Norris Medicines Ltd

Norris Medicines Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating upgraded from Strong Sell to Sell as of 31 July 2026. This change reflects a nuanced shift in the company’s technical outlook, even as fundamental concerns persist. The upgrade is primarily driven by improvements in technical indicators, while valuation and financial trends continue to weigh on investor sentiment.

The 50-day moving average has crossed above the 200-day moving average for Norris Medicines Ltd, signalling a golden cross on 31 Jul 2026. Yet, the stock declined 3.78% on the same day, while monthly momentum indicators remain bearish. This divergence between the moving averages and price action calls for a detailed examination of the signal's reliability.

With a decisive surge to Rs 19.63 on 8 Jul 2026, Norris Medicines Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical signals and sustained price momentum over the past week.

Norris Medicines Limited, a micro-cap pharmaceutical trading and distribution company, reported a net profit of ₹0.05 crores for Q4 FY26 (January-March 2026), marking a dramatic reversal from the ₹0.23 crore loss recorded in the same quarter last year. However, this profitability came against a backdrop of severe revenue contraction, with quarterly net sales plummeting 48.16% year-on-year to ₹1.41 crores. The company's shares, trading at ₹13.25 with a market capitalisation of just ₹14.00 crores, remain under significant pressure as investors grapple with the sustainability of this turnaround.

For the fourth consecutive session, Norris Medicines Ltd has closed lower, culminating in a fresh 52-week low of Rs 12 on 24 Mar 2026. This marks a 14.09% decline over the past four days, underscoring sustained selling pressure despite some pockets of strength in the broader market.

Norris Medicines Ltd’s share price declined sharply to hit a new 52-week low of Rs.12.45 on 23 March 2026, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock’s performance has been under pressure, reflecting a combination of subdued financial metrics and challenging market conditions.

Norris Medicines Ltd has demonstrated a marked turnaround in its financial trajectory during the December 2025 quarter, posting robust revenue growth and record profitability metrics despite a challenging market environment. The company’s financial trend has shifted from flat to positive, signalling renewed operational momentum within the Trading & Distributors sector.

Norris Medicines Ltd, a company operating in the Trading & Distributors sector, recorded a new 52-week low of Rs.12.5 today, marking a significant milestone in its ongoing price decline. This fresh low comes after a sustained period of underperformance relative to both its sector and the broader market indices.

Norris Medicines Ltd’s shares declined sharply to a fresh 52-week low of Rs.12.87 on 21 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial and market performance.

Norris Medicines Ltd touched a fresh 52-week low of Rs.13.5 today, marking a significant decline in its share price amid a sustained downward trend. The stock has underperformed both its sector and the broader market, reflecting ongoing pressures on the company’s financial and market metrics.

Norris Medicines Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Norris Medicines has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that highlight ongoing challenges in its financial and operational performance. The changes in assessment metrics underscore the company’s current position within the Trading & Distributors sector and its microcap status.

Norris Medicines has reached a new 52-week low of Rs.14, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial and market position.

Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning.